Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 28, 2019; 25(32): 4567-4579
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4567
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4567
Treatment options | Indication | Duration | Efficacy | Advantages | Disadvantages |
Pharmacological methods | BMI of ≥ 27 kg/m2 with one obesity related complication or patients with a BMI of ≥ 30 kg/m2 | Varies depending on the agent | 2%-10% weight loss depending on the agent[33] | Mild to moderately effective | Adverse side effect profile dependent on the medication |
Non-invasive | |||||
Reusable | No evidence for long term effectiveness | ||||
Intragastric Balloons | BMI between 30 and 40 kg/m2 | 6 mo | %TBWL 7%-15% | Reversible | High rates of nausea and vomiting |
%EWL 30%-47% | Repeatable | ||||
At 6 mo duration[34] | Can be used in combination of other modalities | Some reports of gastric perforation in rare cases | |||
Aspiration therapy | BMI of 35-55 kg/m2 | Long term duration | %TBWL 14%-18% | Effective | Must see doctors at scheduled intervals |
%EWL 37-54% | Minimal side effects | ||||
From 6-24 mo[35] | Long duration of use | Abdominal pain, peristomal complications | |||
Endoscopic Gastroplasty | BMI between 30 and 40 kg/m2 | Long term follow-up studies in progress | %TBWL 12%-19% | Adaptive new technology with a lot of promise | Requires expertise and technical skills |
At 6-24 mo duration[35] | Minimally invasive | Perigastric fluid collections, extragastric bleeding | |||
Lap Band | BMI of 35 kg/m2 with obesity related complications or BMI of 40 kg/m2 | Reversible | Mean percentage weight loss at 5 yr was 15.9 ± 12.4%[35] | Sustained weight loss at 5 yr | Need for explant up to 12% Vomiting, nausea, dysphagia, GERD |
Improvements in hgb a1c, cholesterol | |||||
Sleeve gastrectomy | BMI of 35 kg/m2 with obesity related complications or BMI of 40 kg/m2 | Permanent, but can be bridged to RYGB | 49%EWL at 5 yr[36] | Long term sustained weight loss | Significant adverse events |
Cardiometabolic risk factor modifying; hyperlipidemia, diabetes | Overall morbidity rate of 19% at 5 yr | ||||
RYGB | BMI of 35 kg/m2 with obesity related complications or BMI of 40 kg/m2 | Permanent | 57%EWL at 5 yr[36] | Long term sustained weight loss | Significant adverse events related to surgery |
Cardiometabolic risk factor modifying; hyperlipidemia, diabetes | Overall morbidity rate of 26% at 5 yr |
- Citation: Glass J, Chaudhry A, Zeeshan MS, Ramzan Z. New Era: Endoscopic treatment options in obesity–a paradigm shift. World J Gastroenterol 2019; 25(32): 4567-4579
- URL: https://www.wjgnet.com/1007-9327/full/v25/i32/4567.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i32.4567